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Ketamine, via intravenous infusions, has emerged as a novel therapy for treatment-resistant 
depression, given rapid onset and demonstrable efficacy in both unipolar and bipolar 
depression. Duration of benefit, on the order of days, varies between these subtypes, but 
appears longer in unipolar depression.  A unique property is reduction in suicidality although 
data are more limited. Strategies to extend duration, via multiple doses, maintenance 
treatment, or subsequent augmenting medications have yielded mixed results. There is a 
relative paucity of data regarding alternate methods of administration such as intramuscular, 
intranasal, and oral routes, though preliminary results are promising.  Adverse effects most 
reliably incl ude dissociative and sympathomimetic effects, both transient and mild, and 
suggest good tolerability. Ketamine's unique effects may represent an opportunity for a 
paradigm shift in the pharmacologic treatment of depression.
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Ketamine and Depression: A Review 
Despite significant progress, depression remains a common and disabling condition that affects millions, leading to increased primary care 
visits and decreased productivity (Baune, Adrian, & 
Jacobi, 2007). Both psychotherapy and antidepressant 
pharmacotherapy are evidence-based treatments 
recommended by experts and treatment guidelines 
(Gelenberg et al., 2010). For those with more severe 
depression, pharmacotherapy is often required for 
recovery. However, inadequate response and lack of 
remission are common, and characterize treatment-
resistant depression (TRD; Keitner and Mansfield, 
2012). The current pharmacopoeia available to clinicians 
is primarily based on modulation of serotonergic, 
noradrenergic, and dopaminergic transmission in the brain, 
with first line agents primarily consisting of selective sero-
tonin reuptake inhibitors (SSRIs; Keitner & Mansfield, 
2012). As demonstrated by the STAR*D study, multiple 
trials of medications are frequently required to achieve 
remission, and despite this, about 35% of patients remain 
symptomatic after several successive interventions (Rush 
et al., 2006; Olin, Jayewardene, Bunker, & Moreno, 
2012). When monoamine modulating antidepressant 
medications do work, there is typically a delay of weeks 
before response is achieved. In those first few weeks, 
antidepressant treatment may increase risk of suicidal 
behavior, and possibly including completed suicide 
(Björkenstam et al., 2013). With the lack of rapid 
response from existing medications, and indeed the 
apparent risk until such response, there is urgent need 
for development of rapid acting treatment alternatives 
for depression (Monteggia, Gideons, & Kavalali, 2013). 
For severe depression, electroconvulsive therapy (ECT) 
is the only somatic intervention with the potential for 
more rapid treatment effect, however concern over 
adverse effects limit use. Alternative approaches utilizing 
direct electrical modulation, including repetitive 
transcranial magnetic stimulation (rTMS), trigeminal 
nerve stimulation, and deep brain stimulation (Cook, 
Espinoza, & Leuchter, 2014) as well as magnetic seizure 
therapy and vagal nerve stimulation (Wani, Trevino, 
Marnell, & Husain, 2013) are promising in terms of 
efficacy, but have not been shown consistently to have a 
more rapid onset of effect than pharmacotherapy.
Studies suggest a role for the glutamate system 
in regulation of mood (Skolnick et al., 1996; Matthews, 
Henter, & Zarate, 2012; Machado-Vieira, Salvadore, 
Diazgranados, & Zarate, 2009), and particular promise 
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has been generated from studies looking at the N-methyl-
D-aspartate (NMDA) receptor antagonist ketamine for 
this novel indication (Artigas, 2013; Zarate et al., 2013; 
Mathew, Manji, & Charney, 2008). Ketamine was 
developed in 1963, first tested on humans in 1964, and 
FDA approved for roles in anesthesia in 1970 (Reich et 
al., 1989; JHP Pharmaceuticals, 2009).  It was not until 
2000 that ketamine was concretely demonstrated in the 
literature to have antidepressant properties (Berman et 
al., 2000).  Ketamine has shown a large effect size, with 
onset on the order of hours, and duration of effect of 
approximately one week (Zarate et al., 2006). Reduction 
in suicidal thoughts is further described, similarly within 
hours of administration (Price et al., 2009; Price et al., 
2014). 
A significant limitation exists in that ketamine 
is only FDA-approved for intravenous (IV) or intra-
muscular (IM) use in induction or maintenance of 
anesthesia, making administration in less controlled 
settings difficult. While most studies on ketamine thus 
far have looked at longer IV infusions, other routes have 
shown promise for increasing patient access to ketamine 
(Larkin & Beautrais, 2011; Harihar, Dasari, & Srinivas, 
2013; Lara, Bisol, & Munari, 2013; Lapidus et al., 2014; 
Iglewicz et al., 2014). 
This article reviews the extant literature 
regarding use of ketamine as an antidepressant, 
highlighting its role as a rapid acting agent for unipolar 
and bipolar depression. We report on and analyze efficacy, 
with additional attention to durability of response, 
improvement in suicidality, routes of administration, 
dosing protocols, and safety. Different stereoisomeric 
forms of ketamine are also reviewed given the possibility 
that one form may be associated with fewer dissociative 
effects. We conclude with recommendations for 
future study design as well as potential off-label use 
in less structured settings. Detailed discussions on the 
history and neuropharmacology of ketamine, and the 
glutamate theory of depression are not included; the 
reader is referred to previous publications on these topics 
(Domino et al., 2010; Krystal, Sanacora, & Duman, 
2013; Caddy. Giaroli, White, Shergill, & Tracy, 2014; 
Naughton, Clarke, Olivia, Cryan, & Dinan, 2014).
Materials and Methods 
PubMed.gov was searched using the term “ketamine depression,” with the filter of English language, 
through March 2015, yielding 1042 studies. Studies 
were excluded that did not investigate clinical use of 
ketamine in humans for treatment of depression, either 
unipolar or bipolar, or suicidality. Those utilizing 
ketamine as an anesthetic or augmenting agent for, or in 
combination with, ECT or rTMS were excluded, as were 
studies regarding the use of ketamine as an augmenting 
agent for psychotherapy, for purposeful alteration of 
consciousness, or in regards to ketamine misuse. The 
remaining articles were further reviewed for pertinent 
references. Data on depression response rates were 
combined and recalculated to include intent to treat 
(ITT) analysis, accounting for differences between rates 
reported in the studies and in this review. To assess for 
ongoing or planned studies a search of ClinicalTrials.gov 
was performed with the terms “ketamine depression.” 
Results
Using the above search criteria, a total of 61 publications from PubMed.gov and 96 from 
ClinicalTrials.gov were identified for inclusion in this 
review. 
Study population and methodology 
 Of these 61 studies, 46 utilized the IV route 
of administration, accounting for over 450 patients in 
total. A further 18 studies utilized IM, oral, intranasal, 
sublingual, or subcutaneous treatment in over 100 
patients. Nearly all publications reported use of racemic 
ketamine, with only 13 patients in total receiving 
S-ketamine (Denk, Rewerts, Holsboer, Erhardt-
Lehmann, & Turck, 2011; Paul, Schaaf, Padberg, 
Moller, & Frodl, 2009; Segmiller et al., 2013; Paslakis, 
Gilles, Meyer-Lindenberg, & Deuschle, 2010). Most 
studies utilized only one administration of ketamine, 
though five open label investigations (OLI) and one 
randomized control trial (RCT) did assess multiple 
doses, from one to three times per week, for up to three 
weeks. The majority of publications reported on patients 
with unipolar depression, though bipolar depression 
was also represented in ten. Given the differences in 
presentation, etiology, and response between these two 
types of depression, these are considered separately. Save 
for a minority of case studies (Table 5; Suppl. Table 1), 
articles utilized one or more validated depression rating 
scales, including the Montgomery-Åsberg Depression 
Rating Scale (MADRS; Montgomery and Åsberg, 1979), 
Hamilton Depression Rating Scale (HDRS; Hamilton, 
1960),  Beck Depression Inventory (BDI; Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961), or Clinical 
Global Impression scale (CGI; Guy et al., 1976). The 
only study to report on the pediatric population utilized 
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ratings scales more specific to that population (Papolos, 
Teicher, Faedda, Murphy, & Mattis, 2013). Studies of 
ketamine in hospice patients also utilized the Hospital 
Anxiety and Depression Scale (HADS; Zigmond & 
Snaith, 1983) (Table 5; Suppl. Table 1). 
 We focused on the categorical outcome of 
response—defined as >50% reduction—within 24 
hours since this was most commonly the primary 
outcome measure referred to in the studies reviewed. 
Remission was not consistently reported, and was also 
variably defined. Notably, too, the majority of these 
studies were performed in patients with treatment 
resistance, and while definitions varied between studies, 
this typically was qualified by at least two, if not more, 
failed trials of adequate dose and duration antidepressant 
treatment. Some also included failure of ECT and only 
few described failure of adequate psychotherapy. To 
objectively assess such trials, many studies utilized the 
Antidepressant Treatment History Form (Sackeim, 
2001). Unless otherwise specified below, we accept the 
authors’ descriptions of TRD. Of the studies employing 
ketamine IV infusions, most utilized racemic ketamine 
0.5mg/kg over 40 minutes, with several more varying the 
duration from 30 to 60 minutes.  For the sake of brevity, 
we abbreviate this protocol as KET in the rest of this 
document.
Efficacy From Single Infusions
The eight RCTs investigating IV ketamine 
included six crossover studies, all with saline placebo, 
and two parallel group designs, both with active controls 
(Table 1). All but one utilized a single ketamine infusion. 
Six were done in patients with unipolar depression and 
the other two in patients with bipolar depression. The 
larger of the two active control and blinded RCTs utilized 
midazolam and included 72 patients in a 2:1 ratio of 
ketamine : midazolam, all with treatment-resistant 
unipolar depression, who were discontinued from any 
concomitant medications.  In the ketamine group, 64% 
responded at 24 hour follow-up, compared to 28% in 
the midazolam group (Murrough, Perez, Mathew, & 
Charney, 2013). Response rate in the ketamine arm 
fell below 50% after day three. The other active control 
blinded RCT utilized ECT as the comparison condition, 
demonstrating a more rapid onset of action and greater 
response rates at 24 hours in the ketamine arm; KET 
elicited 78% response versus 11% with ECT (Ghasemi 
et al., 2013). The other placebo controlled studies in 
unipolar depression generally recruited fewer patients, 
and found  24 hours outcomes of 45% with KET versus 
2% with saline; and 4 hour outcomes of 29% versus 7% 
(Figure 1). 
Both studies of patients with bipolar depression 
were performed by the same group and found more 
rapid onset, but shorter duration, of benefit (Table 1). 
Response was 58% in the first four hours, but by day 
one, half of the cohort no longer met this criterion 
(Figure 2). While studies in unipolar depression generally 
discontinued psychotropic medications and provided a 
washout period, those in bipolar depression maintained 
patients on therapeutic levels of mood stabilizers, either 
lithium or valproic acid, which may have had an effect 
on outcome. 
Limitations in blinding and control selection 
are prevalent in all but Murrough et al. (2013), who 
utilized midazolam as an active control. The trial with 
ECT as the active control (Ghasemi et al., 2013) did 
not appear to have had strict patient blinding, despite 
blinding of the treatment team. Valentine et al. (2011) 
was the opposite, with study personnel being aware 
of experimental conditions. Other studies utilized a 
saline placebo, but the apparent ease in recognition of 
dissociative effects likely sabotaged the blind. 
Seventeen OLIs describe outcomes in unique 
depressed patients after KET, of which sixteen were 
principally in unipolar depression (Table 2). Nearly half 
of the over 250 unipolar depression patients, 95% of 
whom were categorized as TRD, responded within 4-6 
hours after KET (Figure 3). At 24 hours, the overall 
response rate increased to 59% and then gradually 
declined with time. While 4 week outcomes were only 
available for 47 individuals, the 21% response rate after 
a single infusion is remarkable in light of the high degree 
of treatment resistance. Each open-label trial was focused 
on some aspect of KET besides acute antidepressant 
efficacy per se, with several valuable findings. Thakurta 
et al. (2012) demonstrated robust, but short-lived (< 3 
days) antidepressant effects of standard dose KET in an 
Indian population. Ibrahim et al. (2011) demonstrated 
that a history of non-response to ECT was not 
associated with a reduced likelihood of response to KET 
in TRD. Machado-Vieira et al. (2009) did not detect 
change in peripheral blood brain-derived neurotrophic 
factor (BDNF) levels or correlation between BDNF 
and MADRS scores, in 23 TRD subjects over the 
first 4 hours after KET. Salvadore et al. demonstrated 
correlations between short-term antidepressant response 
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Figure 1. Randomized, crossover, controlled trials, response rates in unipolar depression 
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Figure 2. Randomized, crossover, controlled trials, response rates in bipolar depression
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Figure 3. Open Label IV ketamine, response rates in unipolar depression
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to KET and pretreatment signals in prefrontal cortex 
on magnetoenchephalography (2009, 2010) and proton 
magnetic resonance spectroscopy (2012). In support of 
this possibility, Cornwell et al. (2012) demonstrated 
that stimulus-evoked somatosensory cortical magneto-
encephalographic responses were increased after 
ketamine infusion in responders, but not non-responders 
to KET. Phelps et al. (2009) identified another link to 
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Figure 4. Open label and RCT mutidose infusion, response rates in unipolar depression 
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a potential biomarker, demonstrating that non-alcohol-
dependent MDD subjects with a family history of 
alcoholism had a substantially greater likelihood of 
response to KET than those without. Luckenbaugh 
et al. (2012) reported similar findings from a post-
hoc analysis of RCT data (Diazgranados et al., 2010a; 
Zarate et al., 2012).  Both Mathew et al. (2010) and 
Ibrahim et al. (2012) failed to demonstrate benefits from 
randomization to riluzole over placebo during planned 
month-long follow-up treatment after response to open-
label KET. Finally, Larkin and Beautrais (2011) found 
administration of a lower total ketamine dose (0.2 mg/
kg), via IV bolus rather than slow infusion, permitted 
use in an emergency department setting by busy 
clinicians. While they reported cumulative remission 
of 71.4% in the first four hours, improved response 
in the subsequent two weeks must be interpreted in 
light of telephone follow up and naturalistic treatment, 
including inpatient care (this data omitted from the 
table).
The one OLI solely in patients with treatment-
resistant bipolar depression demonstrated progressive 
decreases in mean HDRS score and increases in response 
(Rybakowski, Permoda-Osip, Skibinska, Adamski, & 
Bartkowska-Sniatkowska, 2013; Table 2). Response 
more than doubled from 24% at 1 day to 52% at 1 week, 
remaining stable for the duration of the two week long 
trial. Patients were maintained on a variety of mood 
stabilizing medications, although a limitation of the 
study is that subjects were tapered off of antidepressants 
as recently as 2 weeks prior to KET. This may potentially 
explain the large disparity in outcome data from the 
more rigorously designed RCTs.
Multidose Studies
One RCT and five OLIs assessed multiple 
sequential doses of IV ketamine (Table 3). Of these, 
three utilized a regimen of thrice weekly infusions for 
two weeks. Another utilized up to four infusions, at a rate 
of two per week over two weeks, stopping once patients 
achieved remission. Only one study directly compared 
two different schedules: once weekly versus twice weekly 
infusions over the course of three weeks (Diamond et 
al., 2014). All six noted either stable or increasing rates 
of response over subsequent infusions. The response rate 
for all subjects within 24 hours of their final infusion 
was 59%, though if the outlier is excluded (Diamond 
et al. 2014), this increases to 74%. The majority of 
these studies also reported time to relapse after the final 
infusion, monitoring subjects over the subsequent 4 
weeks or longer, however criteria for relapse varied from 
liberal (aan het Rot et al., 2010) to conservative (Shiroma 
et al., 2014). Summing totals from these studies over 
each time point reveals 50% of patients no longer met 
response criteria between 7-10 days following the final 
infusion, which may potentially underestimate true 
benefit due to our conservative calculations (Figure 4). 
The one RCT compared three ketamine 
infusions with three bilateral ECT treatments over one 
week, finding 89% response rate after three ketamine 
infusions versus 67% with ECT (Ghasemi et al., 
2013). Regarding the five OLIs, all unique patients are 
represented in Murrough et al. (2013), Rasmussen et 
al. (2013), Shiroma et al. (2014), and Diamond et al. 
(2014).  Response rates immediately after conclusion of 
the series of infusions were 71%, 60%, 79%, and 29%, 
respectively (ITT).  Diamond et al. (2014) was again 
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the outlier. Altogether, studies yielded 
a 22% response rate approximately a 
month after conclusion of the course. In 
Murrough et al. (2013), 17% remained 
responders over an additional 3 months 
follow-up, with only one receiving 
other medication in the interim. These 
authors also observed that initial non-
responders (at 4 hours after the first 
infusion) were four times less likely 
than initial responders to achieve 
response at the end of 6 infusions. 
Additionally, several studies noted that 
patients required up to two infusions 
before successfully achieving response 
(Rasmussen et al., 2013; Diamond et 
al., 2014), suggesting that one infusion 
may be insufficient. Rasmussen et 
al. (2013) added to the literature by 
extending 0.5mg/kg infusions over 100 
minutes (0.3 mg/kg/hr), the slower 
rate permitting use without presence 
of anesthesia personnel. Interestingly 
enough, the study with the lowest 
response rate was conducted in an ECT 
recovery room and found that several 
patients complained the setting was too 
noisy, chaotic, or distressing (Diamond 
et al., 2014).  Also notable is that this is 
the only study to use the BDI, a patient 
rated scale, as an outcome measure. 
The other study that was conducted in 
an ECT recovery room had the next 
lowest response rate (Rasmussen et al., 
2013). Diamond et al. (2014) is unique 
in that they assessed memory at baseline 
and after the treatment course, finding 
improvements in autobiographical, 
episodic, and subjective memory. This 
study was also the only one to directly 
compare different treatment regimens, 
though unexpectedly found better 
results with weekly versus twice weekly 
infusions.
Case Reports
The 17 published case studies 
(or judged equivalent) that utilized 
KET comprised just over 30 patients   
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and—save for one dose finding study and another 
comparing racemic versus S-ketamine—typically utilized 
multiple infusions (Suppl. Table 1). These reports on 1-3 
patients describe dramatic improvement in depressive 
symptoms and functioning in patients with TRD 
(Kollmar, Markovic, Thuerauf, Schmitt, & Kornhuber, 
2008; Liebrenz, Borgeat, Leisinger, & Stohler, 2007; 
Liebrenz, Stohler, & Borgeat, 2009); antidepressant 
effect of ketamine even when this was only arrived at 
serendipitously (Ostroff, Gonzales, & Sanacora, 2005); 
several descriptions of prolonged relief of depression 
with repeated dosing (Correll, 2006; Messer et al., 
2010; Murrough et al., 2011); and safe use of ketamine 
in depressed patients with severe medical comorbidities 
or who were concomitantly treated with multiple other 
CNS-acting medications (Kollmar et al., 2008; Liebrenz 
et al., 2007, 2009; Stefanczyk-Sapieha, Oneschuk, & 
Demas, 2008). There were notable examples of rapid 
relief of intense dysphoria and crying in a terminally 
ill cancer patient on a palliative care unit (Stefanczyk-
Sapieha et al., 2008). The cases of Yang, Zhou, Gao, Shi, 
and Yang (2013) demonstrated rapid relief of depression 
in young, drug-naïve men. Szymkowicz, Finnegan, and 
Dale (2013) administered between 16-34 repeated KET 
infusions to three TRD patients over a 12 month period, 
adjusting frequency depending on individual response. 
Their first patient remitted after the 2nd infusion, and 
was maintained so with periodic treatments over the 
subsequent 9 months. Their two other subjects suffered 
repeated relapses despite intermittent courses of repeat 
infusions. Lai et al. (2014) is unique in that it is the 
only dose finding study, comparing 0.1 to 0.4mg/kg of 
ketamine IV over 5 minutes and a saline control, but due 
to low enrollment and poor retention, was placed with the 
cases. Only one of the four individuals displayed a clear 
dose response relationship for antidepressant response, 
though dissociative effects were clearly dose related.
Alternate Routes of Administration 
In contrast to most studies of IV infusion, 
studies into intramuscular, subcutaneous, intranasal, 
oral, and sublingual dosing have mostly utilized multiple 
administrations attempting to extend response (Table 
5).  Bioavailability of these different formulations ranges 
from ~20% for oral, ~30% for sublingual, 45% for 
intranasal, to 93% for intramuscular (Clements, Nimmo, 
& Grant, 1982). Dose, frequency, follow up interval, 
treatment setting, and response metrics varied greatly 
between publications. All patients had their existing 
medications continued, potentially biasing results. 
Onset of benefit was generally rapid in parenteral routes, 
and was successfully maintained with repeat dosing in 
several instances.
In regards to IM administration, one OLI and 
five case studies detailed effects in 25 patients. The 
OLI study (Chilukuri et al., 2014) was notable in that 
it directly compared outcomes from different routes of 
administration (0.5mg/kg IV over 40 minutes, 0.25mg/
kg IM, and 0.5mg/kg IM) and found comparable 
response rates of 33-44% immediately and several days 
after administration. In contrast, in the case reports, 
doses ranged from 0.5mg/kg to 1.0mg/kg, from every 
3-8 days, and from 2-68 treatments. The five patients 
with unipolar depression all met formal criteria for 
response by 24 hours. Glue, Gulati, Le Nedelec, and 
Duffull (2011) also performed a dose-response assessment 
finding greater improvements with higher doses; while 
0.5mg/kg and 0.7mg/kg decreased MADRS scores, only 
1.0mg/kg led to response. Zanicotti, Perez, and Glue 
(2012, 2013) described a woman with metastatic cancer 
and unipolar TRD who, after 1.0mg/kg, experienced 
remission of depression for 5-6 days, and pain for 24 
hours. On a weekly outpatient regimen, response was 
largely maintained for 8 months. Two patients with 
bipolar depression experienced qualitative improvement 
within days to a week after 0.5mg/kg or 0.9mg/kg IM, 
that was maintained for 9-12 months by dosing at 3-4 
day intervals, although one patient did require a dose 
increase after five months (Cusin, Hilton, Nierenberg, 
& Fava, 2012).
Three studies utilized intranasal administration, 
of which one was a double blinded crossover RCT that 
compared ketamine 50mg with saline (Lapidus et 
al., 2014). This study found significant differences in 
MADRS through two days, and a response rate of 44% 
at 24 hours, comparable to other RCTs that utilized 
ketamine infusions (Table 1; Figure 1). The second trial 
was a case series of 12 pediatric subjects (ages 6-19) with 
bipolar TRD that received a dose between 30-120mg. 
Onset of benefit was frequently within the hour, lasting 
for 3-4 days, and maintained for months with once to 
twice weekly dosing (Papolos et al., 2013). The final case 
describes successful long term maintenance of euthymia 
with twice weekly intranasal administration.
The one study on sublingual administration, 
in a mixed cohort of unipolar and bipolar depression, 
utilized a 10mg dose and found “rapid” improvements 
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in 17 of the 26 patients, though the time frame was not 
defined. Using repeat dosing, from every 2-7 days, ten 
patients were described as maintaining response over a 
period of months, based on a Likert scale (Lara et al., 
2013).
Subcutaneous administration has also been 
reported on. McNulty et al. (2012) described a case of 
“dramatic relief” from depression in a hospice patient 
after initial subcutaneous administration of 0.5mg/
kg, followed by the same amount by mouth daily, with 
maintenance for 11 weeks. Another case describes long 
term maintenance of response with repeated doses, 
notably at only 0.2mg/kg (Gálvez et al., 2014). 
Oral, compared to parenteral, ketamine 
administration results in a higher blood norketamine to 
ketamine ratio because of extensive first pass metabolism. 
Norketamine is pharmacologically active as an NMDA 
antagonist and has analgesic and likely antidepressant 
effects. It has longer elimination half-life than ketamine 
itself. The clinical implications for treatment of depression 
are unclear (Blonk, Koder, van den Bemt, & Huygen, 
2010). We found four case studies and a subsequent 
OLI that utilized oral administration. One case study 
(Irwin & Iglewicz, 2010) in two hospice patients with 
depression found response in both after a single dose of 
0.5mg/kg, one within 120 minutes, the other at 8 days. 
The follow-up OLI included 12 additional patients and 
utilized daily dosing of 0.5mg/kg (Irwin et al., 2013), 
finding 57% response rate, mean time to response of 14.4 
days, and maintenance of response for at least 28 days. 
Most recently the same authors published a retrospective 
chart review involving 31 patients finding 71% response 
at 24 hours after single oral doses of 0.5mg/kg (Iglewicz 
et al. 2014). It is unclear why this study displayed such 
rapid  response, while the other did not.  De Gioannis 
and Leo (2014) described use of oral ketamine outside 
the hospice setting, in two individuals with bipolar 
disorder and suicidality, demonstrating maintenance of 
response with escalating doses of oral ketamine every 
two to four weeks. 
S-Ketamine
Ketamine exists as a racemic mixture of the 
S- and R- stereoisomers, and while most studies have 
employed the racemate, a minority has solely used the 
more potent S- stereoisomer. There may be differences 
between the two, both in terms of antidepressant 
response and dissociative effects, though results 
are conflicting. Studies with S-ketamine describe 
treatment in just over ten patients, all with unipolar 
depression (Table 5, Suppl. Table 1). No reports utilizing 
R-ketamine for treatment of depression exist. Only one 
publication, a case report, describes direct comparison 
between stereoisomeric forms of ketamine. Two patients 
were each given equianalgesic IV infusions of racemic 
ketamine 0.5mg/kg and S-ketamine 0.25mg/kg a 
week apart (Paul et al., 2009). Robust antidepressant 
response to both isoforms of ketamine was observed 
in one patient, while the other responded to neither. 
Further, both patients had mild dissociative/perceptual 
disturbances (“psychotomimetic”) with the racemate 
but not S-ketamine. Paslakis et al. (2010) treated four 
individuals with S-ketamine using a total oral daily dose 
of 1.25mg/kg, bioequivalent to 0.25mg/kg IV, divided 
over three times daily and similarly found no dissociative 
effects, and a 50% response rate.  Conversely, subsequent 
studies utilizing IV infusions of S-ketamine 0.25mg/kg, 
either one time or multiple, found comparable response 
rates soon after infusion, but did note strong dissociative 
effects (Denk et al., 2011; Segmiller et al., 2013).
Suicidality 
The data regarding reduction of suicidality with 
ketamine is generally suggestive of benefit (Table 4). The 
majority of studies did not assess suicidality as a primary 
outcome measure, and also utilized group mean change 
in suicidality scales rather than more easily interpretable 
results such as percent of the cohort achieving lack of 
suicidality. In regards to unipolar depression, three 
RCTs and nine OLIs reported on suicidality, typically 
utilizing either the HDRS or MADRS suicide items, 
or the scale for suicide ideation (SSI; Beck, Kovacs, & 
Weismann, 1979). Of these, only one OLI reported lack 
of benefit. The others showed benefit at disparate time 
points ranging from the first four hours post dose to three 
days out. Time course data is present in only one study, 
with loss of significance after four hours. Four studies, 
however, reported categorical outcomes of percent of 
subjects attaining an SSI or MADRS-SI score below 
a certain threshold (resolution of suicidal thoughts). 
These “response rates” ranged from 81% to 90% within 
the first 24 hours. Another study found, at 4 hours, a 
97% response rate in 33 previous ketamine responders, 
and a 100% response among the high suicidality sub-
cohort (Diazgranados et al., 2010b). Price et al. (2014) 
reanalyzed data from the Murrough et al. (2013) RCT, 
finding decreases in both explicit suicidality as well as 
implicit associations (“Escape = Me”). Other case reports, 









Placebo arm Number of 
doses
NIMH 2004, July recruiting parallel MDD or 
bipolar













The University of 
New South Wales











Yale University 2012, March recruiting crossover MDD or 
bipolar II, and 
alcohol dep.
no HDRS IV infusion / 40min 0.5mg/kg saline single
Columbia 
University












2012, May enrolling by 
invitation
parallel MDD yes HDRS IV infusion / 45min 0.25mg/kg scopolamine 






2012, June completed 
(unpub-
lished)
parallel MDD yes MADRS IV infusion / 40min 0.5mg/kg / vari-
able frequency 
of doses
saline / variable 
frequency of 
doses





2012, August ongoing, not 
recruiting





2012, August recruiting parallel SI no SSI IV infusion 0.2mg/kg saline single
Mayo Clinic 2012, Sep-
tember





oral 0.5mg/kg unclear single
New York State 
Psychiatric Institute
2012, October recruiting parallel MDD no unspecified 
SI scale






2013, May recruiting parallel MDD yes HDRS IV infusion / 40min 0.5mg/kg saline single
University of 
Ottawa




Mount Sinai School 
of Medicine







2013, August recruiting parallel MDD yes HDRS IV infusion 0.1, 0.2, 0.5, 
and 1.0mg/kg
midazolam single























2014, January ongoing, not 
recruiting
parallel MDD or SA yes unspecified 
SI measure




2014, July not yet open parallel SI no MADRS, 
SSI
intranasal 0.2mg/kg saline given in one 






not yet open parallel MDD and SI, 
age >65











2015, Jan not yet open parallel MDD yes MADRS IV infusion / 40min 0.5mg/kg, 3x/wk 
for 2wks
5 midazolam 
infusions and 1 
ketamine infusion
comparing 
one versus 6 
infusions
Table 6. Ongoing and planned studies, Part 1. Randomized and double blind control studies













2010, June unknown open label MDD yes MADRS IV infusion / 40min 0.5mg/kg single
Massachusetts 
General Hospital
2012, April ongoing, not 
recruiting
open label MDD and SI yes HDRS IV infusion / 45min 0.5mg/kg, then 
0.75mg/kg for 
nonresponders




2012, April unknown open label MDD or bipolar yes MADRS, HDRS, SSI IV infusion / 40min 0.5mg/kg single
New York State Psy-
chiatric Institute





2013, August recruiting open label SA, age 12-18 no QIDS-C, CGI IV infusion / 15min 0.5mg/kg single
University of 
Minnesota
2014, February recruiting open label MDD, age 12-18 yes CGI IV infusion / 100min 0.5mg/kg 3x/wk for 2 weeks
Mayo Clinic 2014, March recruiting open label MDD or bipolar, 
and SI
yes MADRS IV infusion / 100min 0.5mg/kg 3x/wk for 2wks, then 
weekly for 4wks
NIMH 2014, April recruiting open label, 
parallel [1]
MDD yes MADRS IV infusion / 40min 0.5mg/kg single
UCLA 2014, June recruiting open label MDD yes MADRS, HDRS IV infusion / 40min 0.5mg/kg single
Sheba Medical 
Center
2014, August not yet open open label MDD yes MADRS IV infusion 0.5mg/kg unclear
Yale University 2014, 
November
not yet open open label MDD or bipolar yes Extinction Learning 
Task performance
IV infusion unclear 2x/wk for 2 wks, with 
CBT for 8 wks
utilizing IV infusions (Murrough et al., 2011; Zigman 
& Blier 2013), and a case series with IM administration 
(Harihar et al., 2013), all showed benefit. Conversely, 
one OLI of oral ketamine in 14 hospice patients found 
no such benefit (Irwin et al., 2013).
In bipolar depression, two RCTs and two case 
series report on suicidality. The two RCTs, both by 
the same group, conflict in finding significant benefit. 
Zarate et al. (2012) demonstrated significant differences 
in between-group MADRS-SI scores through three days. 
Diazgranados et al. (2010a), on the other hand, found 
no difference between IV ketamine and placebo, though 
these authors excluded patients with risk for suicide at 
baseline. One case series utilized IM administration and 
showed qualitative improvement (Cusin et al., 2012), 
while the other did so with oral doses every two to four 
weeks (De Gioannis & Leo, 2014).
Adverse Effects 
During infusion, two adverse events with 
ketamine led to discontinuation in RCTs (Suppl. Table 
2): hypotension and bradycardia, and hypertension 
unresponsive to beta-blockers (Murrough et al., 
2013). Following infusion, four adverse events led to 
discontinuation: worsening mood in three patients 
(one with suicidal ideation), and increased anxiety in 
the other (Diazgranados et al., 2010a). Two placebo 
patients discontinued, one each during infusion and 
after infusion for elevated blood pressure (Valentine et 
al., 2011) and hypomania (Diazgranados et al., 2010a), 
respectively. In OLIs, only two adverse events led to 
treatment discontinuation out of nearly 300 individuals 
(Suppl. Table 3): elevated blood pressure unresponsive 
to beta-blockers during infusion (Murrough et al., 
2013), and a panic attack (Diamond et al., 2014). In case 
reports, one subject receiving S-ketamine at 0.25mg/
kg discontinued during infusion due to dissociation 
(Segmiller et al., 2013).
Tachycardia and transient elevations in blood 
pressure were commonly reported hemodynamic effects 
in RCTs and OLIs, though two cases of hypotension 
(Murrough et al., 2013; aan het Rot et al., 2010), one 
case of bradycardia (aan het Rot et al., 2010), and one 
vasovagal episode were also reported. Aan het Rot et 
al. (2010) also reported one patient with bradypnea, 
with oxygen desaturation to 94%. To date, no RCTs or 
OLIs have reported these effects persisting beyond four 
hours, save for one patient with mild, asymptomatic 
hypotension lasting until discharge at 24 hours (aan het 
Rot et al., 2010).
Dissociation, psychotomimetic effects, manic 
symptoms, and other psychiatric effects were assessed in 
most investigations. In RCTs and OLIs adverse effects 
Table 6. Ongoing and planned studies, Part 2. Open label studies
[1] Study will compare outcomes between those with and without family history of alcoholism.
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as measured by Clinician Administered Dissociative 
Symptom Scale (CADSS; Bremner et al., 1998), Brief 
Psychiatric Rating Scale (BPRS; Overall & Gorham, 
1962) or Young Mania Rating Scale (YMRS; Young, 
Biggs, Ziegler, & Meyer, 1978) revealed significant 
increases compared with control/baseline, that generally 
resolved by 80 min to four hours. 
In the four OLIs utilizing repeat dosing, changes 
in CADSS and BPRS were similar after each infusion, 
with no progressive increase with multiple infusions. 
Similarly, hemodynamic and respiratory effects did not 
worsen with repeat administrations. Dose dependent 
increases in dissociative symptoms were reported in one 
ascending dose study, in which rapid IV infusions over 
two to five minutes were used (Lai et al., 2014). Transient 
tachycardia and asymptomatic premature ventricular 
contractions were described in one patient, and nausea 
and vomiting in another (aan het Rot et al., 2010; 
Shiroma et al., 2014). One suicide attempt occurred 
during the washout period before ketamine infusion 
(Murrough et al., 2013). One report of mania was found 
in a patient who received 34 doses of ketamine at variable 
intervals over a 1 year period (Liebrenz et al., 2009), and 
another reported a “mild” hypomanic episode in a patient 
after his third infusion (Diamond et al., 2014). Niciu 
et al. (2013) analyzed data from three NIMH RCTs 
of IV ketamine infusion in bipolar depression, finding 
transient increases in YMRS scores lasting no more than 
a day after infusion, and no cases of full blown mania or 
hypomania.  They also reported that within the YMRS 
elevations, none of the patients had specific elevations in 
the elevated mood item (Suppl. Table 2).
Adverse effects in case reports were consistent 
with those of RCTs and OLIs. Events uniquely described 
in the case reports include the following: less pronounced 
dissociation on a second dose compared to the first 
(Liebrenz et al., 2009; Clark et al., 2014), hypomania 
in one patient (Szymkowicz et al., 2013), “delirium” 
for 5-8 minutes following 0.5mg/kg bolus (Yang et al., 
2013), and in a report of two patients, psychotomimetic 
effects during racemic but not S-ketamine infusions 
(Szymkowicz et al., 2013).
Intramuscular reports noted effects similar to 
those of IV, without mention of hemodynamic changes. 
In one case, decrease in dizziness and derealization 
occurred over repeat (41 total) injections (Zanicotti 
et al., 2013), whereas in another a dose of 1.0mg/kg 
resulted in intolerable dissociative effects necessitating a 
dose decrease to 0.5mg/kg (Cusin et al., 2012). In one 
intranasal study of 12 pediatric patients, transient (60 
minutes) dissociative effects similar to IV were reported, 
as well as mild palpitations and moderate respiratory 
distress (Papolos et al., 2013), whereas in another 
intranasal case report the patient described feeling 
“high,” but only during the first few of more than thirty 
administrations (Clark et al., 2014). Sublingual dosing 
in 26 patients resulted in no euphoria, psychotic, or 
dissociative symptoms. Lightheadedness (mild, transient, 
and improving on repeat dosing) and one report of 
tachycardia (<30 minutes) occurred. Mouth numbness 
was the only novel effect reported (Lara et al., 2013). In 
the 50 patients that received oral ketamine, essentially 
no adverse effects, including vital sign changes, were 
reported (Paslakis et al., 2010; Irwin & Iglewicz, 
2010; Irwin et al., 2013), save for disorientation and 
hallucinations in a minority of a medically ill hospice 
population (Iglewicz et al., 2014). In fact, there were 
improvements in BPRS and adverse symptom checklists 
(Irwin & Iglewicz, 2010). Only diarrhea, trouble 
sleeping, and “trouble sitting still” occurred (one each) 
in a study of 14 patients (Irwin et al., 2013). The only 
study of oral S-ketamine, divided over three times daily, 
found essentially no side effects in all four patients.
Ongoing and Planned Studies
A review of ClinicalTrials.gov yielded five OLIs 
and twenty RCTs (Table 6). Add-on oral medication 
as a potential method for extension of benefit is being 
investigated in a total of four studies: lithium, venlafaxine, 
minocycline, and d-cycloserine. Multiple dose regimens 
are being studied in nine trials, and suicidality is being 
studied in five. Four are assaying escalating doses, 
variable number of infusions, or increasing duration of 
infusion. The majority utilize ketamine IV infusions, 
while three are using intramuscular, intranasal, oral, or 
subcutaneous methods of administration. In only one 
study did we find a plan to include more than one route 
of administration. All studies utilize racemic ketamine.
Discussion 
Discussion is divided into consideration of anti-depressant and antisuicidal effects, adverse effects, 
ketamine's stereoisomers, further clinical issues, and 
recommendations for future research.
Antidepressant and antisuicidal effects
Ketamine appears to have remarkably robust 
efficacy in short-term relief of severe and treatment-
resistant depression, with onset in hours, and duration 
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of at least a few days. While this has been observed in 
both unipolar and bipolar depressed populations, in 
the latter, duration appears slightly shorter and there 
are fewer supporting studies. Similarly, in cases of 
non-TRD, this effect seems to hold, though relative 
efficacy is unclear. Ketamine’s effectiveness in relief of 
acute suicidal ideation is also a highly valuable finding, 
though with less support. This benefit appears unique to 
ketamine among available treatment options, although 
comparisons with other active treatments are lacking. 
Furthermore, there are conflicting findings as to whether 
reductions in suicidality are specific, or rather related 
to overall reductions in depression (Price et al., 2009; 
Diazgranados et al., 2010b; Rasmussen et al., 2013; 
Murrough et al., 2013). Studies for the most part have 
excluded individuals with recent suicidality, and instead 
performed post-hoc reanalyses of suicidality subscales, 
though future studies are enrolling high risk individuals 
for targeted therapy with ketamine (Table 6). To date 
there are no data on suicide attempts, completed suicide, 
or other long-term effects, nor on parasuicidal behavior. 
Despite the limited amount of data, this is fertile ground 
for further research given the great potential benefit 
to treat emergent suicidality or avert hospitalization. 
Ketamine deserves consideration for use in select patients 
who otherwise would continue to suffer severely, if only 
as a temporizing measure to give clinicians time to 
identify and implement alternative treatments.  
The largest challenge with this promising agent 
remains the extension of benefit for the longer term, 
which is pertinent to the vast majority of depressed 
patients who have failed to benefit sufficiently from 
psychotherapy, psychosocial interventions, and the 
initial tiers of somatic intervention. Repeated ketamine 
infusions have shown some promise, and there may 
be a cumulative dose effect similar to ECT, where a 
series of treatments are required to induce full response 
or remission (aan het Rot et al., 2010; Murrough et 
al., 2013; Rasmussen et al., 2013). Indeed, several 
studies concluded patients require more than one 
infusions before being considered non-responders. The 
comparison to ECT is tempting, and certainly makes 
for a good argument against those who would dismiss 
the potential for ketamine in depression because of the 
only short-term benefit of single infusions. It is far from 
clear what the optimum dose, frequency, and number of 
infusions will be, and how this might be individualized, 
though future studies will be revealing. It also worth 
noting that some patients do not benefit from ketamine, 
despite multiple treatments (Szymkowicz, Finnegan, & 
Dale, 2014).
Alternatives to IV infusion, such as intra-
muscular (IM), intranasal(IN), oral, sublingual (SL), 
and subcutaneous (SC) routes, have been ástudied to a 
lesser extent, but do appear to work, with the trade-off 
of potentially lower response rates with all routes other 
than the IM, which results in ketamine bioavailability 
similar to IV administration. A significant limitation is 
lack of high quality prospective studies: of these alternate 
routes, our review found only one RCT, which utilized 
IN administration (Lapidus et al., 2014). Compared with 
IV administration, IM, IN, and SL routes are similarly 
rapid acting, with conflicting and weaker data for SC and 
oral administrations. Duration of benefit is similar to IV 
infusions, on the order of days, but has been successfully 
prolonged with repeated dosing, which is notably easier 
given the relatively low resource requirements with such 
administrations. Several cases describe treatment in an 
office-based setting, with patients returning to the office 
anywhere from multiple times a week to once a month, 
and maintaining response on the order of months. It is 
unclear if such response eventually fades, or rather if it 
could be continued indefinitely, though several cases 
describe maintenance for nearly a year (Zanicotti et al., 
2013; Cusin et al., 2012). Oral dosing, while used mostly 
in hospice populations, appears to have slower onset of 
benefit, though an initial loading dose via a rapid acting 
route of administration could be combined with more 
convenient maintenance daily oral administration, as in 
one case report (McNulty et al., 2012). 
Adverse effects
Ketamine appears to be well tolerated, the 
most commonly reported adverse effects being transient 
dissociative and psychotomimetic experiences.  As noted 
in several studies, patients appear to become tolerant to 
such effects after several subsequent administrations, 
and yet maintain a similar antidepressant response 
(Berman et al., 2000; Paul et al., 2009; Luckenbaugh 
et al., 2014). Occasionally, hemodynamic effects, 
typically transient and mild, have led to treatment 
discontinuation although in every case these have 
responded to conservative management. There does not 
appear to be a correlation between hemodynamic effects 
and antidepressant response (Luckenbaugh et al., 2014). 
In our review, sublingual, intranasal, and especially oral 
administration generally resulted in fewer adverse effects 
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than seen after IV administration, and may be due to a 
slower increase in blood levels (Lara et al., 2013; Paslakis 
et al., 2010; Irwin & Iglewicz, 2010; Irwin et al., 2013; 
Iglewicz et al., 2014). Supporting this possibility, Lai et 
al. (2014), found extensive dissociative symptoms with IV 
administration over 2 minutes, leading them to mitigate 
this issue by extending administration over five minutes. 
The safety profile of short-term ketamine, particularly in 
closely monitored settings, is reassuring. 
There is however a relative paucity of data on 
ketamine's adverse effects in the long-term treatment of 
depression. Long-term exposure in abuse populations, 
where dose and frequency far exceed those used in 
clinical protocols, does suggest potentially serious 
sequelae. In such populations, both short- and long- 
term neurocognitive adverse effects have been reported 
(Curran & Monaghan, 2001; Morgan, Monaghan, & 
Curran, 2004). Conversely, data from studies utilizing 
ketamine for treatment of depression indicate that it 
may actually improve neurocognitive outcomes, most 
likely by reversing the “pseudo-dementia” seen in severe 
depression (Permoda-Osip, Kisielewski, Bartkowska-
Sniatkowska, & Rybakowski, 2015; Shiroma et al., 2014). 
Lower urinary tract symptoms (LUTS) appear to be a not 
infrequent problem in long-term abusers of ketamine, 
and include urinary frequency, urge incontinence, 
dysuria, urgency, and hematuria (Chu et al., 2008; 
Shahani, Streutker, Dickson, & Stewart, 2007). Severe 
sequelae have been reported including interstitial cystitis, 
papillary necrosis, and irreversible renal failure. In chronic 
pain patients and abusers, LUTS have been reported as 
early as five months, although symptoms may begin in 
as little as nine days (Chu et al., 2008; Storr & Quibell, 
2009; Grégoire, Maclellan, & Finley, 2008). One large 
prospective cohort study surveyed 3,806 recreational 
users, 1,285 of whom had used ketamine in the year 
prior. LUTS was reported in 340 (26.6%) in a dose and 
frequency related pattern. Resolution with abstinence 
occurred in 51% of cases, and continued deterioration 
occurred in 3.8% (Wein, 2013). Mechanisms for these 
effects are unknown. In our review, only one complaint 
of urinary tract symptoms was found, cystitis, and 
judged to be caused not by ketamine, but rather sexual 
activity (Diamond et al., 2014). Another setting in which 
ketamine’s rapid onset of antidepressant—in addition 
to analgesic—effects has been used with success is the 
inpatient palliative care setting (Prommer et al., 2012, 
Iglewicz et al., 2014), though concern has been raised 
that in the cancer patients, ketamine’s mTor upregulation 
could accelerate tumor growth (Yang, Zhou, & Yang, 
2011). In treatment of bipolar depression, another 
important adverse effect to monitor for is induction of 
mania or cycle acceleration. As noted in the Niciu et al. 
(2014) review of three larger NIMH trials, this was not 
found to be a serious concern, however long-term data in 
this area are completely lacking. 
Ketamine’s Stereoisomers
Ketamine exists as a racemic mixture of the 
S- and R- stereoisomers, yet these appear to have subtly 
different effects. S-ketamine has long been known to 
have approximately 2-3 times greater potency in terms 
of analgesia and anesthesia (Kohrs & Durieux, 1998), 
and 3-4 times greater affinity for the PCP binding site 
of the NMDA receptor, but only negligible binding to 
the sigma receptor. R-ketamine on the other hand, has 
greater, although still weak, sigma receptor binding, 
but the significance of this is unclear (Vollenweider, 
Leenders, Oye, Hell, & Angst, 1997). Observations 
from the anesthesia literature initially noted that in 
equianalgesic doses, S-ketamine has a lower incidence 
of psychotomimetic side effects than either the racemate 
or R-stereoisomer (Raeder et al., 2000), leading some 
to investigate it for depression. Both the racemate and 
S-ketamine appear to have antidepressant effects, but 
data regarding psychotomimetic effects of the component 
stereoisomers are more contradictory. A separate series 
of trials may perhaps explain this; one pilot study of 
healthy individuals found that the dose of S-ketamine 
required to induce psychosis is 60% of that of the 
racemate, suggesting the S-enantiomer is responsible for 
such effects (Vollenweider et al., 1997). These authors 
found psychotomimetic effects in S-ketamine versus “a 
state of relaxation” in R-ketamine (Vollenweider et al., 
1997). Animal studies assessing equimolar equivalents 
of each stereoisomer found both to provide a rapid and 
long lasting antidepressant effect, but ultimately a longer 
durability of effect with the R-enantiomer, leading them 
to speculate the R- form may be a good candidate for 
future study (Zhang, Li, & Hashimoto, 2014; Hashimoto 
et al., 2014).  Further research directly comparing S-, R-, 
and racemic ketamine is needed to clarify if one indeed 
exhibits fewer dissociative effects while still maintaining 
antidepressant efficacy.
Further Clinical Issues
There is no uniform definition of treatment 
resistance in the literature reviewed, although patients 
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with or without treatment resistance, however defined, 
respond similarly. In assessing improvements in 
depression, the most commonly used measures—the 
MADRS and HDRS—may not adequately assess change 
over a time scale on the order of hours.  Several questions, 
for example regarding sleep and appetite, cannot reflect 
change over the course of a 40 minute infusion; some 
studies have gotten around this by carrying forward 
prior subscores  (Rasmussen et al., 2013). The issue of 
concomitant medications—or their discontinuation—
is another confound which will need to be carefully 
managed in the design of future long term studies.
Several potential predictors of response have 
received attention. Our review suggests that both 
bipolar and unipolar depressed patients may exhibit 
short term response to ketamine. Besides the potential 
for pharmacologic differences between the S- and R- 
enantiomers discussed above, ketamine is hepatically 
metabolized to norketamine, which also has neurotrophic 
effects and psychopharmacologic properties. The import-
ance of this is unclear; Sos et al. (2013) found no correlation 
between blood levels of ketamine or norketamine and 
antidepressant response. Several authors have suggested 
that the melancholic subtype of major depression may 
augur a greater likelihood of response, but this not been 
studied prospectively (Paslakis et al., 2010; Atigari & 
Healy, 2013; Gálvez et al., 2014). Multiple studies found 
a greater likelihood of antidepressant response in TRD 
patients with a family history of alcoholism, compared 
to those without, although no relationship to personal 
history of alcoholism was seen (Phelps et al., 2009; Niciu 
et al., 2014). Ionescu, Luckenbaugh, Niciu, Richards, & 
Zarate (2014) found greater response in anxious versus 
non-anxious unipolar depression, but in a separate post-
hoc analysis in bipolar depression found no difference 
between the anxious and non-anxious subtypes. At least 
in bipolar depression, this is notable because those with 
the anxious subtype are frequently poorer responders 
to conventional treatment. To this end, in studies of 
conditions previously classified as anxiety disorders, 
such as post-traumatic stress disorder and obsessive-
compulsive disorder, ketamine has also shown benefit 
(Feder et al., 2014; Rodriguez et al., 2013).
To date, other agents directed at the 
neurochemical system most frequently held to account 
for ketamine’s antidepressant effect—NMDA receptor 
antagonism—have been disappointing in terms of 
extending ketamine’s short-term benefits (Ibrahim et al., 
2012; Mathew et al., 2010; Zarate et al., 2006; Heresco-
Levy et al., 2006). Additional trials are underway to 
explore this strategy, although infusion of a specific 
NMDA antagonist, AZD6765, was not effective (Zarate 
et al., 2013). Alternative mechanisms, such as ketamine’s 
effects on seizure threshold, are worth considering 
(Atigari & Healy, 2013). 
An obvious question is how dissociative and 
antidepressant effects might be related. Our review found 
that the time course of these effects differs substantially, 
and antidepressant effects can occur in patients who do 
not experience even transient dissociative effects and 
vice-versa. One post-hoc analysis found that magnitude 
of acute dissociative symptoms partially correlated with 
later antidepressant response (Luckenbaugh et al., 2014). 
Thus, the dissociative effects are not necessarily part of the 
antidepressant effects per se. On the other hand, it is worth 
considering that this dissociation is part of the unique 
effect of ketamine that is not shared by conventional 
antidepressants: an altered sense of self that can also lead 
to a new state of contentment. This could explain why 
recent trials with non-psychoactive NDMA antagonists 
have not demonstrated antidepressant efficacy, and may 
in fact represent an as yet unexplored aspect of mood 
regulation—what might be called the eudaimonic 
dimension ( or "well-being," from Aristotle)—that 
ketamine has given the field an opening to better explore. 
Companion articles in this current issue expand on this 
notion in much more depth. It is also worth noting that 
nitrous oxide and classic hallucinogens, share similar 
dissociative/psychotomimetic and antidepressant 
effects with ketamine (Nagele et al., 2014; Baumeister, 
Barnes, Giaroli, & Tracy, 2014). Similarly, ketamine 
and the classic hallucinogens have each been employed 
in end of life care, either for depression or anxiety, 
but perhaps with a similar mechanism (Iglewicz et 
al., 2014; Gasser et al., 2014; Grob et al., 2011). It 
may be the case, as with classic hallucinogens, which 
were originally termed psychotomimetic, that these 
altered states are less “psychotic mimicking” and more 
psychedelic, or “mind manifesting.” In the case of classic 
hallucinogens, concerns over these effects led their 
potential antidepressant benefit to be ignored for many 
years (Baumeister et al., 2014).
A corollary issue pertinent to ketamine’s 
unique effects is what has been called “set and setting” 
(Johnson, Richards, & Griffiths, 2008). That is, the 
mind sets of the provider and the patient, and the 
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environmental setting in which the treatment session 
occurs, may have particularly important impact on 
treatment outcome. Consistent with this, two studies 
conducted in noisy, crowded, high intensity medical 
settings had the poorest outcomes among the studies of 
multiple ketamine infusions (Rasmussen et al., 2013; 
Diamond et al., 2014). Conversely, recent studies of 
MDMA-assisted psychotherapy for post-traumatic stress 
disorder (Mithoefer et al., 2013) and psilocybin for end 
of life anxiety (Grob et al., 2011) used carefully designed 
protocols to optimize these aspects of the interventions. 
It is possible that similar optimization of ketamine 
treatment would improve antidepressant outcomes.
Several unanswered questions remain in the 
clinical use of ketamine for depression.  Is the presence of 
an anesthesiologist required? By extending the duration 
of the ketamine infusion to 100 minutes anesthesiology 
monitoring was determined to be unnecessary 
(Rasmussen et al., 2013).  Another study reports infusions 
were performed by a psychiatrist with Basic Life Support 
training and code team backup (Zigman & Blier, 
2013). A further question, as alluded to in discussion of 
alternate routes, is whether ketamine could be used in an 
office-based setting: the RCT using intranasal ketamine 
amended their protocol after demonstrated safety, 
and began discharging individuals four hours after 
receiving their doses (Lapidus et al., 2014). Furthermore, 
several case reports utilizing IM and other methods of 
administration describe successful long-term treatment 
in an office-based setting. Ultimately, more rigorous 
studies in such settings are needed.  
Ketamine has not yet been formally promoted 
for general clinical use but has seen growing use among 
psychiatrists in private practice and academic centers. 
Providers hoping to utilize ketamine for treatment of 
depression should take care to offer full informed consent 
as well as communicate that this use is off-label from 
FDA approved indications of ketamine. There is a relative 
paucity of data on both the effectiveness and safety in the 
outpatient setting, though case reports suggest this can 
successfully be done. Existence of an abuse population 
must also be considered when expanding ketamine use 
to this setting. Further, there are serious safety concerns 
from the abuse and pain management literature, as noted 
above. Our review provides strong suggestive support 
for the use of more “user friendly” alternatives to IV 
infusion, but caution is warranted.
Recommendations for future research 
Based on this review, the following specific 
recommendations stand out: 
1)   Trials to further assess if benefit seen in TRD 
extends to non-treatment refractory depression. 
2)  Direct comparisons between various routes of 
administration, both in acute and maintenance 
treatment, as well as to both placebo or standard 
agents.
4)    Trials to specifically assess anti-suicidal effects, 
in both acute and maintenance treatment.
5)  Dose-response relationships for each route of 
administration, including monitoring of levels 
of both ketamine and norketamine levels.
6)  Examination of optimal dosing frequencies for 
all routes of administration, with the goal of 
extending duration of response
7)  Systematic monitoring of psychotomimetic and 
dissociative effects with long-term treatment, 
and correlations with responses to treatment, 
including whether tachyphylaxis to these effects 
may occur.
8) Systematic monitoring of neuropsychological 
functions, urinary tract related symptoms, 
suicidal behavior, and at least in bipolar subjects, 
mood switching, during long term treatment.
9)  Careful analysis of ketamine’s “eudaimonic” effects 
as they relate to antidepressant, dissociative, 
psychotomimetic, and antisuicidality effects.
10) Additional trials to follow-up on the suggested 
benefits of ketamine in other disorders such as 
PTSD and OCD; and as a transpersonal agent 
for those with life threatening illness and at the 
end-of life.
Conclusion
A thorough review of the literature utilizing ketamine for treatment refractory depression reveals rapid 
onset of action in the first several hours, often lasting 
several days to a week, after a single infusion. We 
acknowledge a common criticism raised about the 
limited time frame of efficacy from a single dose of 
ketamine, however this does not distinguish it from any 
other treatment of depression, including psychotherapy, 
medication, or ECT. Furthermore, multiple dosing 
studies and alternate routes of administration have 
safely and successfully extended the antidepressant 
benefit of ketamine, with select cases demonstrating 
maintenance for nearly a year. These findings are all 
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the more impressive when viewed from the perspective 
of an already treatment-resistant population. While 
the existing paradigm of 40 minute IV infusions has 
proven limitedly effective, much less resource intensive 
protocols such as intranasal, intramuscular, oral, and 
subcutaneous methods of administration represent a 
potential revolution in the use of ketamine. These routes 
of administration have the advantage of expanding 
ketamine research to the outpatient setting. We did not 
find evidence of serious neurocognitive adverse effects in 
clinical use, in contrast to what has been reported with 
ketamine abuse. This is an area in which ketamine may 
distinguish itself from ECT as an alternative for TRD. 
Similarly, we did not find evidence of LUTS, but this 
has not been systematically investigated. The frequency 
and seriousness of LUTS in the abuse population makes 
it an important adverse effect to monitor in future long 
term studies.Dissociative effects are common, time 
limited, generally well tolerated, and appear to subside 
in intensity with repeat dosing. These and other unique 
effects, distinguish it from currently used monoaminergic 
antidepressants and warrant further study in terms of 
their ability to advance understanding of depression and 
its treatment. Significant hemodynamic effects requiring 
intervention are possible but uncommon, and do require 
careful monitoring. Potential contraindications do exist, 
including psychosis, abuse liability, and hemodynamic 
instability, but with care in patient selection unwanted 
outcomes can be minimized. Ketamine is clearly a very 
promising agent. While we must urge caution in wide 
spread clinical application before further research is 
completed, our review of the risks and benefits supports 
its use in carefully selected cases who have not benefited 
from other treatments.
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